ATE536186T1 - Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel - Google Patents

Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel

Info

Publication number
ATE536186T1
ATE536186T1 AT04817764T AT04817764T ATE536186T1 AT E536186 T1 ATE536186 T1 AT E536186T1 AT 04817764 T AT04817764 T AT 04817764T AT 04817764 T AT04817764 T AT 04817764T AT E536186 T1 ATE536186 T1 AT E536186T1
Authority
AT
Austria
Prior art keywords
insulin
growth factor
deficiency
igf
treatment
Prior art date
Application number
AT04817764T
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Tercica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tercica Inc filed Critical Tercica Inc
Application granted granted Critical
Publication of ATE536186T1 publication Critical patent/ATE536186T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
AT04817764T 2003-09-12 2004-09-09 Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel ATE536186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50257903P 2003-09-12 2003-09-12
PCT/US2004/029735 WO2005049792A2 (en) 2003-09-12 2004-09-09 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency

Publications (1)

Publication Number Publication Date
ATE536186T1 true ATE536186T1 (de) 2011-12-15

Family

ID=34619295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04817764T ATE536186T1 (de) 2003-09-12 2004-09-09 Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel

Country Status (18)

Country Link
US (3) US7258864B2 (de)
EP (2) EP2274978B1 (de)
JP (1) JP4738337B2 (de)
CN (2) CN102861321A (de)
AT (1) ATE536186T1 (de)
AU (1) AU2004291833B2 (de)
CA (1) CA2538342C (de)
DK (1) DK2274978T3 (de)
ES (2) ES2373783T3 (de)
HU (1) HUE027218T2 (de)
IL (1) IL174209A (de)
MA (1) MA28091A1 (de)
NZ (1) NZ545940A (de)
PL (1) PL2274978T3 (de)
PT (1) PT2274978E (de)
TN (1) TNSN06082A1 (de)
WO (1) WO2005049792A2 (de)
ZA (1) ZA200602183B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861321A (zh) * 2003-09-12 2013-01-09 特西卡股份有限公司 胰岛素样生长因子-1(igf-1)缺陷的治疗方法
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
CA2643529C (en) * 2008-11-06 2019-05-21 Kenneth W. Adams Method and composition for enhancement of male erectile function
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US8759299B2 (en) 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011150228A1 (en) * 2010-05-26 2011-12-01 The Children's Hospital Of Philadelphia Research Institute Compositions and methods for the diagnosis and treatment of primary insulin-like growth factor deficiency (pigfd) and idiopathic short stature (iss)
US20130302909A1 (en) * 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP3233109A4 (de) * 2014-12-16 2018-07-18 Puretein Bioscience, LLC Verfahren zur steigerung des serum-igf-1-spiegels bei einem tier
WO2019075404A2 (en) * 2017-10-13 2019-04-18 The Metrohealth System IGF-1 (INSULIN GROWTH FACTOR) AS A THERAPY FOR CARDIAC ARRHYTHMIAS
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
CN111954966A (zh) 2018-04-10 2020-11-17 坦德姆糖尿病护理股份有限公司 用于对医疗设备进行感应充电的系统和方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
ATE95236T1 (de) 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
WO1988007863A1 (en) 1987-04-06 1988-10-20 Biogrowth, Inc. Human somatomedin carrier protein subunits and process for producing them
DE3850995T2 (de) 1987-04-23 1995-03-16 Monsanto Co Sekretion eines dem Insulin ähnlichen Wachstumsfaktors in E. coli.
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
WO1989005822A1 (en) 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
ATE151293T1 (de) 1991-08-01 1997-04-15 Genentech Inc Igf-i zur verbesserung der neuronale lage
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
KR100354897B1 (ko) 1993-12-23 2003-01-06 노보 노르디스크 에이/에스 성장호르몬방출성을갖는화합물
CN1052730C (zh) 1993-12-23 2000-05-24 诺沃挪第克公司 具有生长激素释放特性的化合物
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
WO1996037514A1 (en) 1995-05-26 1996-11-28 Theratechnologies Inc. Chimeric fatty body-pro-grf analogs with increased biological potency
WO1997039032A1 (en) 1996-04-17 1997-10-23 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
CN102861321A (zh) 2003-09-12 2013-01-09 特西卡股份有限公司 胰岛素样生长因子-1(igf-1)缺陷的治疗方法

Also Published As

Publication number Publication date
WO2005049792A3 (en) 2006-02-23
PL2274978T3 (pl) 2015-11-30
CN102861321A (zh) 2013-01-09
IL174209A (en) 2012-12-31
US8133862B2 (en) 2012-03-13
DK2274978T3 (en) 2015-06-15
NZ545940A (en) 2009-12-24
US7517530B2 (en) 2009-04-14
HUE027218T2 (en) 2016-10-28
AU2004291833B2 (en) 2010-08-26
MA28091A1 (fr) 2006-08-01
AU2004291833A1 (en) 2005-06-02
US20090270323A1 (en) 2009-10-29
ZA200602183B (en) 2007-07-25
EP1667521B1 (de) 2011-12-07
IL174209A0 (en) 2006-08-01
ES2541673T3 (es) 2015-07-23
JP2007505140A (ja) 2007-03-08
JP4738337B2 (ja) 2011-08-03
PT2274978E (pt) 2015-07-09
EP1667521A2 (de) 2006-06-14
US7258864B2 (en) 2007-08-21
EP2274978A1 (de) 2011-01-19
CN1870893A (zh) 2006-11-29
TNSN06082A1 (en) 2007-10-03
EP2274978B1 (de) 2015-05-20
US20050059598A1 (en) 2005-03-17
EP1667521A4 (de) 2008-07-02
CA2538342C (en) 2013-01-08
ES2373783T3 (es) 2012-02-08
WO2005049792A2 (en) 2005-06-02
US20080058259A1 (en) 2008-03-06
CA2538342A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
ATE536186T1 (de) Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
Khandelwal et al. Conventional SLA and chemically modified SLA implants in patients with poorly controlled type 2 diabetes mellitus–a randomized controlled trial
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
DE69841907D1 (de) Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
ATE64530T1 (de) Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
Crescentini et al. Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: a review
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
EP1444516A4 (de) Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
Ko et al. Effects of implant healing time on crestal bone loss of a controlled-load dental implant
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
US6818665B2 (en) Treatment of obstructive sleep apnea
DE60229240D1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE69723982D1 (de) Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms
Fukuta et al. Invasiveness of tibial bone graft harvesting for secondary alveolar bone grafting: Can harvesting be performed at the age of less than 10 years without complications?
Alhamdani et al. Influence of Patient’s Age and Gender on Dental Implant Treatment Five Year retrospective study
DE60141759D1 (de) Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
DE60131100D1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
Aksoy et al. Distribution and pattern of implant therapy in a part of the Turkish population
Naseri et al. Clinical outcomes of dental implants placed in fresh sockets: A five-year retrospective study
Salles et al. Oriental Medicine Technique in the Treatment of Stress and Quality of Life in Patients with Chronic Problems
SU1316684A1 (ru) Способ лечени астенических состо ний у больных неврастенией